Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case-control study.

Authors:
Santeramo R; Damiani C; Wei J; Montana G; Brentnall AR.

Journal:
Breast Cancer Res

Publication Year: 2024

DOI:
10.1186/s13058-024-01775-z

PMCID:
PMC10848404

PMID:
38326868

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Breast Cancer Res

Abbreviation: Breast Cancer Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive…
Nie J; Dang S; Zhu R and 2 more (2024) - Transparency Score: 3/6
Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black w…
Zirpoli GR; Pfeiffer RM; Bertrand KA and 3 more (2024) - Transparency Score: 3/6
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable o…
Shatsky RA; Batra-Sharma H; Helsten T and 14 more (2024) - Transparency Score: 4/6
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in ea…
López-Velazco JI; Manzano S; Otaño M and 8 more (2024) - Transparency Score: 3/6
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breas…
Rodón J; Demanse D; Rugo HS and 9 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe data used in this manuscript were fully anonymized and made available for research following ethical approval from the NHS Health Research Agency (REC reference: 19/SC/0284, IRAS reference: 265403). Competing interestsAB declares income from Cancer Research UK arising from commercial use of the Tyrer-Cuzick (IBIS) breast cancer risk evaluator. Competing interests AB declares income from Cancer Research UK arising from commercial use of the Tyrer-Cuzick (IBIS) breast cancer risk evaluator."

Evidence found in paper:

"Funding The work of RS, JW and CD was supported by Cancer Research UK (Grant reference: C49757/A28689, awarded to GM and ARB)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025